Active CMV disease does not always correlate with viral load detection

Bone Marrow Transplantation

Volumn 40, Issue 1, 2007, Pages 55-61

  Ruell, J ^a   Barnes, C ^a   Mutton, K ^a   Foulkes, B ^a   Chang, J ^a   Cavet, J ^a   Guiver, M ^a   Menasce, L ^b   Dougal, M ^b   Chopra, R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CARMUSTINE; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; MELPHALAN; MESNA; METHOTREXATE; PENICILLIN V; PENTAMIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SALBUTAMOL; THYMOCYTE ANTIBODY; VIRUS DNA; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE COURSE; DRUG HYPERSENSITIVITY; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD;

EID: 34347396788     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705671     Document Type: Article

References (26)

1. Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson k, Lonnqvist B et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66: 1330-1334.
2. Holmberg L, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94: 4029-4035.
3. Humar A, Lipton J, Welsh S, Moussa G, Messner H, Mzzulli T et al. A randomised trial comparing cytomegalovirus antigenemia assay vs. screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Bone Marrow Transplant 2001; 28: 485-490.
4. Machado CM, Dulley FL, Boas LS, Castelli JB, Macedo MC, Silva RL et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy. Bone Marrow Transplant 2000; 26: 413-417.
5. Razonable R, Emery VC. 11th Annual meeting of the IHMF. Management of CMV infection and disease in transplant patients, 27-29 February, 2004. Herpes 2004; 11: 77.
6. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA et al. pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 1996; 88: 4063-4071.
7. Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-763.
8. Leruez-Ville M, Ouachee M, Delarue R, Sauget AS, Blanche S, Buzyn A et al. Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time pcr assay performed with blood plasma. J Clin Microbiol 2003; 41: 2040-2046.
9. Guiver M, Fox A, Mutton K, Mogulkoc N, Egan J. Evaluation of CMV viral load using TaqMan™ CMV quantitative PCR and comparison with CMV Antigenemia in heart and lung transplant recipients. Transplantation 2001; 71: 1609-1615.
10. Solano C, Munoz I, Gutiérrez A, Farga A, Prosper F, Gacia-Conde J et al. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 2001; 39: 3938-3941.
11. Chopra R, Linch DC, McMillan AK, Blair S, Patterson KG, Moir D et al. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol 1992; 81: 197-202.
12. Kessinger A, Bierman P, Vose J, Armitage J. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 1991; 78: 3330.
13. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
14. Razonable R, Emery V. Management of CMV infection and disease in transplant patients. Herpes 2004; 11: 77-86.
15. Crippa F, Holmberg L, Carter RA, Hooper H, Marr KA, Bensinger W et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 281-289.
16. Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 2001; 27: 877-881.
17. Martinelli G, Agazzi A, Laszlo D, Santoro P, Mancuso P, Pruneri GC et al. Idarubicin containing regimen in multiple myeloma: Preliminary results of a pilot study using a modified "TANDEM" transplant program. Leuk Lymphoma 2003; 44: 299-302.
18. Martino R, Caballero MD, Canals C, San Miguel J, Sierra J, Rovira M et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 341-347.
19. Howden BP, Michaelides A, Spelman DW, Spencer A, Schwarer AP, Wesselingh S et al. Cytomegalovirus viral load monitoring after allogeneic bone marrow transplantation in patients receiving antiviral prophylaxis. Bone Marrow Transplant 2003; 32: 795-800.
20. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
21. Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121-3127.
22. Davies JK, Hubertus C, Duarte F et al. Reduced intensity conditioning unrelated donor transplantation for very high risk haematological malignancies - a single Centre experience (abstract form). Blood 2003; 102: Abstract 3594.
23. DiPersio JF, Link D, Devine S. Mobilisation of allogeneic stem cells. ASH Education Program Book. Hematology 2003: 419-432.
24. Couban S, Simpson DR, Barnett M, Bredeson C, Hubesch L, Howson-Jan K et al. A randomised multicentre comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1531.
25. Schmitz N, Beksak M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761-767.
26. Nye MB, Leman AR, Meyer ME, Menequs MA, Rothberg PG. Sequence diversity in the glycoprotein B gene complicates real time PCR assays for detection and quantification of cytomegalovirus. J Clin Microbiol 2005; 43: 4968-4971.